Navigation Links
Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented
Date:11/3/2008

TAMPA, Fla., Nov. 3 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that studies of two investigational drugs in development for treatment of potentially blinding eye diseases will be presented at upcoming ophthalmology meetings: At the American Uveitis Society's annual invitational meeting (November 9, Atlanta Marriott Marquis, Atlanta), preliminary results will be presented from an anterior uveitis trial that compared Sirion's ophthalmic corticosteroid Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% dosed four times daily (QID) to Pred Forte(R)* (prednisolone acetate ophthalmic suspension) 1%, dosed eight times daily. Durezol was approved by the US Food and Drug Administration in June 2008 for the treatment of inflammation and pain associated with ocular surgery.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )

In addition, data for Sirion's ophthalmic gel formulation of ganciclovir as a treatment for herpetic keratitis will be presented in a poster at the American Academy of Ophthalmology (AAO) Meeting (November 8-11, Atlanta). The poster's author is Herbert E. Kaufman, M.D., Ophthalmologist Emeritus of Sirion Therapeutics and formerly Professor of Ophthalmology and Pharmacology and Head of the Department of Ophthalmology at LSU Medical Center, and past president of the Association for Research and Vision in Ophthalmology (ARVO), the International Society of Refractive Surgery (ISRS) and the Contact Lens Association of Ophthalmologists (CLAO).

"We're proud to have products in late-stage clinical testing for two of the leading causes of blindness, uveitis and ocular herpes," said Barry Butler, President and CEO of Sirion Therapeutics, Inc. "These medications have the potential to reduce suffering and save the vision of thousands of patient each year, and exemp
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Many Heart Attack Patients Dont Get Best Emergency Treatment

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...HAM, Mass., Nov. 25 According to M...ty on medical technology market intelligence, the ...vices will continue to see rapid growth over the n...n. MRG,s US Markets for Trauma Devices 2010 re...amic over the next five years, with competitors in...
(Date:11/25/2009)...FT, The Netherlands and JOHANNESBURG, November 25 ...ivision and Pyxis Discovery announced today,that t...ly market both,companies, services. , Pyx...discovery expertise,will be coupled with iThemba,s...ic chemistry support to projects identified throug...
(Date:11/24/2009)...lif., Nov. 24 Endologix,...asive treatments for aortic disorders, announced t...tinue all proceedings in, the patent infringement ..., Inc. The motion was filed in the United States ...ologix has requested that the stay remain in effec...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Health Connect Partners Hosts Hospital O R 26amp 3B Surgery Center Conference 61003 1Health Connect Partners Hosts Hospital O R 26amp 3B Surgery Center Conference 61003 2LG Electronics New Line of HDTVs for Long Term Care Facilities Signal Transition From Resident Owned to Facility Owned HDTVs 61001 1LG Electronics New Line of HDTVs for Long Term Care Facilities Signal Transition From Resident Owned to Facility Owned HDTVs 61001 2LG Electronics New Line of HDTVs for Long Term Care Facilities Signal Transition From Resident Owned to Facility Owned HDTVs 61001 3LG Electronics New Line of HDTVs for Long Term Care Facilities Signal Transition From Resident Owned to Facility Owned HDTVs 61001 4LG Electronics New Line of HDTVs for Long Term Care Facilities Signal Transition From Resident Owned to Facility Owned HDTVs 61001 5Award winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 60999 1Award winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 60999 2Award winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 60999 3Award winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 60999 4Award winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 60999 5Award winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 60999 6
...ril 17 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS...y at the,21st International Conference on Antivira...dated preclinical data on ANA598, a non-nucleoside...ymerase., The presentation reported several precl...tial for beneficial combination of the product can...
...es Expansion of Company,s Phase 3 Study for Wet AM...ty Data, FREMONT, Calif., April 17 NeoVista, Inc...nistration (FDA) has granted the,company,s request...s,pivotal Phase 3 trial from 10 to 30 in the Unite...Secondary to AMD Treated with BEta RadiatioN,Epire...
Other Medicine Technology:Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research 2Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research 3FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 2FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 3
(Date:11/28/2009)...ect circadian rhythm, , , FRIDAY, N...hat an internal body clock that goes on the fritz ...sorder in children. , The finding results from...dren with bipolar disorder, which can make people ... without the disorder. They linked variations in a...
(Date:11/27/2009)...wswire-FirstCall/ -- GSI Group Inc. (Pink Sheets: ...hnology products and semiconductor systems, today ...shareholders has been scheduled for Friday, April ...ll be announced in due course. As previously anno...rom Stephen Bershad, a holder of greater than ten ...
(Date:11/27/2009)...likins Ltd. today issued its latest biochemical an...hat the lethality of the virus has dropped from it...t outbreak in the spring of 2009 to resting non-ep...1 infectivity count, however, remains increased. ...27, 2009 -- Biotech firm Replikins Ltd., which has...
(Date:11/27/2009)...ire-FirstCall/ -- The Gymboree Corporation (Nasdaq...ill present at the NASDAQ OMX 23rd Investor Progra...don, England, on Wednesday, December 2, 2009, at 1... of The Gymboree Corporation,s presentation over t...ick on "Our Company" at the bottom of the page, go...
(Date:11/27/2009)...ov. 27 Team Garmin-Slipstream, the...d to ethical sporting and developing the next gene...it will become Team Garmin-Transitions with the ad...the team. Transitions Optical is the world,s leadi...most advanced photochromic technology in the wides...
Breaking Medicine News(10 mins):Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:GSI Group Calls Shareholders Meeting 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3
...nacional,S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" ...ter ("OTC") pharmaceuticals and personal care prod... of the personal hair care product line,Ma Evans. ...the product in the market through its distribution...
...rk It Out (DKWIO), a,dynamic 501(c)(3) not-for-pro...spiritual wellness of children, today announced th...erations. Ms. Secco will employ her more than ten ...ing message. , "Childhood obesity continues ...
...logy is often touted as the "cure" for health care... issued today warns that implementation of techno...ccess, and may actually jeopardize the quality and...able, choosing the right technology, understanding...
...sdaq: PURE ), creators of the patented silver di...ed revenues for the fiscal quarter ended October,3...300 in the same quarter,last year. The Company re....04) per share, in the first fiscal quarter last,y...
...ne before 39 weeks unless necessary, study says , ...te preterm birth puts newborns at increased risk f.... , Dr. Joann Petrini of the March of Dimes and c...reterm babies (those born between 34 weeks and 36 ...
...hma problems and death, agency officials warn , ... safety of four asthma medications will be weighed...el as two days of hearings end Thursday. , The con...nder 17. , One expert thinks the problem is not wi...
Other Medicine News:Health News:Genomma Lab Announces the Successful Launch of the Ma Evans Brand 2Health News:Danialle Karmanos' Work It Out Names Tracey Secco as Director of Operations 2Health News:Joint Commission Alert: Prevent Technology-Related Health Care Errors 2Health News:Joint Commission Alert: Prevent Technology-Related Health Care Errors 3Health News:PURE Bioscience Reports First Quarter Results 2Health News:PURE Bioscience Reports First Quarter Results 3Health News:PURE Bioscience Reports First Quarter Results 4Health News:PURE Bioscience Reports First Quarter Results 5Health News:PURE Bioscience Reports First Quarter Results 6Health News:Late Preterm Birth Poses Developmental Risks 2Health News:FDA Panel Mulls Safety of Asthma Meds 2Health News:FDA Panel Mulls Safety of Asthma Meds 3
...PROVISION Surgical Helmet System from DePuy offers...tion. This system helps meet OSHA recommendations ...fluids, while creating a new standard for comfort....SION Helmet System from DePuy, is a personal prote...
Single Disc Electrodes
Thru-the-Lens Headlight Video Imaging System
Ring Electrodes
Medicine Products: